Introduction
Individuals infected with the human immunodeficiency virus HIIV) are reported to have an increased susceptibility to bacterial infections including Streptococcus pneumoniae . The incidence of bacterial pneumonia in HIV infected intravenous drug abusers is reported to be particularly high'. Immunisation of HIV infected persons with polyvalent pneumococcal polysaccharide vaccines (PPPV) is recommended by the Department Of Health (UK)4 and the Centre For Disease Control (Atlanta).' However, efficacy has never been assessed by clinical trials in this immunocompromised group. Indeed, vaccine failure has been reported in AIDS. ' Several lines of evidence indicate that protection against Streptococcus pneumoniae largely depends on the possession of specific IgG2 antibody. IgG2 is the major isotype produced in response to polysaccharide antigens in adults (before 10 
